This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
by Zacks Equity Research
Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.
Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales
by Zacks Equity Research
Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.
Amgen (AMGN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 1.07% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
by Zacks Equity Research
Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
Take the Zacks Approach to Beat the Market: NVIDIA, Carrols, CyberArk in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
by Zacks Equity Research
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
Unlocking Q4 Potential of Amgen (AMGN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) reachead $314.26 at the closing of the latest trading day, reflecting a -0.11% change compared to its last close.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.
Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.
Will Amazon's (AMZN) Q4 Earnings Benefit From AWS Momentum?
by Zacks Equity Research
Amazon's (AMZN) fourth-quarter results are likely to reflect benefits from AWS' expanding customer base, driven by the strong services portfolio and rising number of cloud regions.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $310.26, marking a +1.56% move from the previous day.
Amgen Inc. (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
The Zacks Analyst Blog Highlights Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson
by Zacks Equity Research
Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson are included in this Analyst Blog.
Top Research Reports for Novartis, Amgen & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).